MODERN ASPECTS OF ENDOMETRIOSIS TREATMENT. USE OF DIENOGEST
https://doi.org/10.21518/2079-701X-2017-13-54-56
Abstract
Dienogest is a highly effective drug for treating the major pain symptoms of endometriosis (chronic pelvic pain, dyspareunia and dysmenorrhea) and preventing a relapse with a high safety profile and good tolerability allowing to indicate it for longterm treatment of the disease. The latest data reflecting the full impact on the various links of the pathogenesis disease testify in favour of the choice of the specified progestagen.
About the Authors
E. G. Khilkevich
Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD,
Moscow
O. I. Lisitsyna
Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Begum T, Chowdhury SR. Aetiology and pathogenesis of endometriosis – a review. Mymensingh Med. J., 2013, 22(1): 218–21.
2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis, Fertility and Sterility, 2012, 98(3): 511–519.
3. Giudice L, Kao L. Endometriosis. Lancet, 2004, 364(9447): 1789–99.
4. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obs. Gynecol Clin North Am., 1997, 24(2): 235–58.
5. The Practice Committee of the American Society of Reproductive Medicine, Treatment of pelvic pain associated with endometriosis: A committee opinion, Fertil. Steril., 2014, 101(4): 927–935.
6. Nnoaham KE, Hummelshoj L, Webster P,’Hooghe TD, De Cicco Nardone F, De Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT. Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries, Fertil. Steril., 2011, 96(2)6 366–373.e8.
7. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum. Reprod., 2013, 28(6): 1552–1568.
8. Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills., Fertil. Steril., 2017, 107(3): 533–536.
9. Oettel M, Carol W, Elger W, Kaufmann G, Moore C, Romer W, Klinger G, Schneider B, Schroder J, Sobek L, Walter F, Zimmermann H. A 19-norprogestin without 17(alpha)-ethinyl group II: Dienogest from a pharmacodynamic point of view, Drugs of Today, 1995, 31(7): 517–36.
10. Klipping C, Duijkers I, TA F, SF K, Schuett B. Pharmacodynamic study of four oral dosages of dienogest. Fertility and Sterility, 2010, 94(suppl 1, 4): S181, Abstract P-304.
11. Чернуха Г.Е. Современные прогестагены в лечении эндометриоза (обзор международных исследований). Проблемы репродукции, 2012, 4: 68–71.
12. Yamanaka K, Xu B, Suganuma I, Kusuki I, Mita S, Shimizu Y, Mizuguchi K, Kitawaki J. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E 2 production in human endometriotic stromal cells in spheroid culture. Fertil. Steril., 2012, 97(2): 477–482.
13. Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol. Endocrinol., 2014, 3590, 9: 1–5.
14. G R Attia, K Zeitoun, D Edwards, A Johns, B R Carr, and S E. Bulun, Progesterone receptor isoform A but not B is expressed in endometriosis. J. Clin. Endocrinol. Metab., 2000, 85(8): 2897–2902.
15. Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, Okuda K, Ohmichi M. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J. Ovarian Res., 2012, 5(1): 31.
16. Grandi G, Mueller MD, Bersinger NA, Facchinetti F, McKinnon BD. The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. Gynecol. Endocrinol., 2017, 0(0): 1–4.
17. Grandi G, Mueller M, Bersinger N, Papadia A, Nirgianakis K, Cagnacci A, McKinnon B. Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells. Am. J. Reprod. Immunol., 2016, 76(4): 292–298.
18. Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm. Res., 2016, 65(3): 183–192.
19. Nirgianakis K, Grandi G, McKinnon B, Bersinger N, Cagnacci A, Mueller M. Dienogest mediates midkine suppression in endometriosis. Hum. Reprod., 2016, 31(9): 1981–1986.
20. Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil. Steril., 2015, 104(3): 655–664.
21. Saito F, Tashiro H, Yamaguchi M, Honda R, Ohba T, Suzuki A, Katabuchi H. Development of a mouse model for testing therapeutic agents: The anticancer effect of dienogest on endometrial neoplasms. Gynecol. Endocrinol., 2016, 32(5): 403–407.
22. Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, Isaka K. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis, J. Obstet. Gynaecol. Res., 2016, 42(9): 1152–1158.
23. Yamanaka A, Hada T, Matsumoto T, Kanno K, Shirane A, Yanai S, Nakajima S, Ebisawa K, Ota Y, Andou M. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis, Eur. J. Obstet. Gynecol. Reprod. Biol., 2017, 216: 51–55.
24. Maiorana A, Incandela D, Parazzini F, Alio W, Mercurio A, Giambanco L, Alio L. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch. Gynecol. Obstet., 2017.
25. Park SY, Kim SH, Chae HD, Kim C-H, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months, Clin. Exp. Reprod. Med., 2016, 43(4): 215.
26. Adachi K, Takahashi K, Nakamura K, Otake A, Sasamoto N, Miyoshi Y, Shioji M, Yamamoto Y, Fujitani M. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol. Endocrinol., 2016, 32(8): 646–649.
27. Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet. Gynecol. Sci., 2016, 59(6): 506–511.
28. Доброхотова Ю.Э., Гришин И.Г., Ибрагимова Д.М., Нуруллин Р.Ф. Опыт применения Визанны у пациенток с диагностированным эндометриозом. Проблемы репродукции, 2014, 33–35.
29. Ярмолинская М.И., Беженарь В.Ф. Опыт применения диеногеста в комбинированном лечении генитального эндометриоза. Фарматека, 2013, 3: 48–51.
30. García Uranga-Romano A, Hernández-Valencia J, Zárate M, Basavilvazo-Rodríguez MA. Dienogest usefulness in pelvic pain due to endometriosis. A meta-analysis of its effectiveness. Rev Med Inst Mex Seguro Soc., 2017, 55(4) 452–455.
Review
For citations:
Khilkevich EG, Lisitsyna OI. MODERN ASPECTS OF ENDOMETRIOSIS TREATMENT. USE OF DIENOGEST. Meditsinskiy sovet = Medical Council. 2017;(13):54-56. (In Russ.) https://doi.org/10.21518/2079-701X-2017-13-54-56
Views:
632
Email this article 